前列腺特异性膜抗原相关放射性核素偶联药物临床评价的研究进展

Progress in the Clinical Evaluation of Prostate-specific Membrane Antigen-associated Radionuclide-coupled Drugs

前列腺癌(PCa)是男性最常见的恶性肿瘤之一。其以前列腺特异性膜抗原(PSMA)高表达为特征。针对PSMA靶点的放射性核素偶联药物(RDCs)是当今PCa研究中的热点,近年来发展迅速,并在PCa诊断和治疗中发挥重要作用,多种新型PSMA相关RDCs进入临床研究。鉴于放射性药物的特殊性,在进行临床综合评价时,必须考虑电离辐射的影响。该文综述近10年来PSMA相关RDCs的临床研究,并重点介绍PSMA相关RDCs临床研究中药品综合评价的内容和方法。

Prostate cancer(PCa)is one of the most common malignant tumors in men,marked by the high expression of prostate-specific membrane antigen(PSMA).Radionuclide drug conjugates(RDCs)targeting the PSMA antigen have become a hot topic in PCa research.The development of PSMA-targeted RDCs has progressed rapidly in recent years,significantly contributing to the diagnosis and treatment of PCa.Numerous novel PSMA-related RDCs are now part of clinical research.Due to the special properties of radiopharmaceuticals,it is essential to consider the impact of ionizing radiation in comprehensive clinical evaluation.This article,review the clinical studies from the past decade,and discusses the scope and methodologies of comprehensive clinical evaluation for PSMA-related RDCs.